W. R. Grace & Co

W. R. Grace & — Merger or Acquisition (February 2021)

11 slides from W. R. Grace &'s merger presentation, Feb 26, 2021

  1. Slide 1: Grace Expands Fast Growing Pharma Portfolio: Grace to Acquire Albemarle's Fine Chemistry Services Business

    Slide 1: Grace Expands Fast Growing Pharma Portfolio: Grace to Acquire Albemarle's Fine Chemistry Services Business

    Grace Expands Fast Growing Pharma Portfolio Grace to Acquire Albemarle’s Fine Chemistry Services Business February 25, 2021

  2. Slide 2: Statement Regarding Safe Harbor For Forward-Looking Statements

    Slide 2: Statement Regarding Safe Harbor For Forward-Looking Statements

    2021 W. R. Grace & Co. | 2 Statement Regarding Safe Harbor For Forward-Looking Statements This announcement contains forward-looking statements, that is, information related to future, not past, events. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “e

  3. Slide 3: Transaction Overview

    Slide 3: Transaction Overview

    2021 W. R. Grace & Co. | 3 Attractive Valuation Financial Flexibility Strategically Compelling Timing / Closing Considerations ▪ $570 million purchase price, 9.5x full year run-rate 2021 EBITDA multiple ▪ Funded with $300 million in cash and $270 million in non-participating preferred equity ▪ Finan

  4. Slide 4: Accelerates Strategy of Building Higher Growth Portfolio

    Slide 4: Accelerates Strategy of Building Higher Growth Portfolio

    2021 W. R. Grace & Co. | 4 Accelerates Strategy of Building Higher Growth Portfolio Accretive to revenue growth rate, EBITDA margin, and Adjusted EPS in 2021 at attractive valuation – Accretive revenue growth rate with EBITDA margins >35% – $570 million purchase price with ~$60 million full year run

  5. Slide 5: Highly Complementary to Existing Pharma Portfolio

    Slide 5: Highly Complementary to Existing Pharma Portfolio

    2021 W. R. Grace & Co. | 5 Highly Complementary to Existing Pharma Portfolio The Pharma business is the largest, fastest growing and most profitable business within Materials Technologies Leading supplier of silica materials and fine chemicals for global Pharmaceutical, Nutraceutical, and Agricultur

  6. Slide 6: Strategically and Financially Compelling Acquisition

    Slide 6: Strategically and Financially Compelling Acquisition

    2021 W. R. Grace & Co. | 6 Strategically and Financially Compelling Acquisition 62%16% 22% Albemarle’s Fine Chemistry Services Business (“FCS”) develops and manufactures high-value regulatory starting materials (RSMs), intermediates, and active pharmaceutical ingredients (APIs) ▪ Key end-markets inc

  7. Slide 7: Grace Offers A Compelling Investment Opportunity

    Slide 7: Grace Offers A Compelling Investment Opportunity

    2021 W. R. Grace & Co. | 7 Grace Offers A Compelling Investment Opportunity So Much More Than Refining Catalysts We are successfully building a higher growth portfolio ▪ SC and MT combined are 62% of our 2020 sales, 66% larger than RT ▪ RT's robust cash flow is a valuable asset that helps fund our g

  8. Slide 8: Appendix

    Slide 8: Appendix

    Appendix GRACE Talent | Technology | Trust

  9. Slide 9: Appendix: Definitions and Reconciliations of Non-GAAP Measures

    Slide 9: Appendix: Definitions and Reconciliations of Non-GAAP Measures

    2021 W. R. Grace & Co. | 9 Appendix: Definitions and Reconciliations of Non-GAAP Measures Non-GAAP Financial Measures (A) In the above, Grace presents financial information in accordance with U.S. generally accepted accounting principles (U.S. GAAP), as well as the non-GAAP financial information des

  10. Slide 10: Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued)

    Slide 10: Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued)

    2021 W. R. Grace & Co. | 10 Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued) Non-GAAP Financial Measures In the 2020 first quarter, the definition of Adjusted EBIT was modified to adjust for the effects of interest and taxes on equity in earnings of unconsolidated affiliate

  11. Slide 11: Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued)

    Slide 11: Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued)

    2021 W. R. Grace & Co. | 11 Appendix: Definitions and Reconciliations of Non-GAAP Measures (continued) Non-GAAP Financial Measures Grace is unable without unreasonable efforts to estimate the annual mark-to-market pension adjustment or future net income or diluted EPS. Without the availability of th

Source: SEC EDGAR · 8-K filed Feb 26, 2021

More decks from W. R. Grace & Co